Selected Publications

Fraktalkine axis in oncology

• Publication

  Positive research results for KAND567 may pave the way for new treatment for ovarian cancer

  Lehto J, Huguet Ninou A, Chioureas D, Jonkers J, Gustafsson NMS.

  Targeting CX3CR1 Suppresses the Fanconi Anemia DNA Repair Pathway and Synergizes with Platinum.

  Read Publication
• Publication

  Study in primary samples from cancer with progressive disease show that KAND567 has capacity to kill leukemic cells by blocking specific immune cells in the leukemia microenvironment

  Mohammad Hojjat-Farsangi MSc,PhD , Wen Zhong Ms.C, Tom Mulder MD PhD, Ann Svensson Ms.C, Jeanette Lundin MD PhD, Marzia Palma MD PhD, Johan Schultz PhD, Thomas Olin PhD, Bjorn Wahlin MD PhD, Anders Osterborg MD PhD, Parviz Kokhaei PhD, Hakan Mellstedt MD PhD

  A CX3CR1 (fractalkine receptor) Small Molecular Antagonist (rugocrixan) Suppressed the Growth Promoting Effect of Monocytes on Chronic Lymphocytic Leukemia Cells

  Read Publication